Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Pasithea Therapeutics Corp. (KTTA)

Pasithea Therapeutics names Kartik Krishnan chief medical officer effective May 1

Neutral Impact 3 of 5 leadership Written later

Pasithea Therapeutics Corp. appointed Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer, effective May 1, 2026, to oversee clinical development and medical strategy for its lead drug candidate PAS-004 in neurofibromatosis type 1. The Board also approved stock option awards on May 1, 2026, at an exercise price of $0.841 per share, including 1,129,323 options for Dr. Krishnan.

Key points

  • Dr. Krishnan, age 55, previously served as Chief Executive Officer at OncoNano Medicines and as Chief Medical Officer at Arcus Biosciences.
  • Initial annual base salary of $500,000, with a discretionary bonus of up to 40% of base salary; employment is at-will and includes severance in specified circumstances.
  • Options for 1,129,323 shares at $0.841 per share vest 33% on the one-year anniversary of the May 1, 2026 grant date, with the remainder vesting quarterly over the following two years.
  • Four non-employee directors each received options for 152,783 shares at $0.841 per share, vesting in full on the one-year anniversary of the grant date.

The filing

CompanyPasithea Therapeutics Corp. (KTTA)
Form8-K, current report
Filed with the SECMay 4, 2026, 5:00 PM ET
Accession number0001213900-26-051681

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.